Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study
Sponsor: Daewoong Pharmaceutical Co. LTD.
Summary
This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg in Korean patients with dyslipidemia in real-world clinical practice. Patients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.
Official title: A Prospective, Non-interventional, Multi-center Observational Study to Evaluate the Efficacy and Safety of Baroezet Tablet 1/10 mg in Korean Patients With Dyslipidemia
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
12000
Start Date
2026-04-30
Completion Date
2027-12-31
Last Updated
2026-04-07
Healthy Volunteers
No
Conditions
Locations (1)
Multiple centers in Republic of Korea
Seoul, South Korea